Marty Metz, MD, explores and reflects on results from the REMIX 1 and 2 studies, which evaluated the impact of remibrutinib (Rhapsido, Novartis) on symptom relief and control of chronic spontaneous urticaria (CSU).
advertisement
Remibrutinib For Treating Chronic Spontaneous Urticaria
Share
Save
Restart
Resume
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Recommended
Details
Overview
Marty Metz, MD, explores and reflects on results from the REMIX 1 and 2 studies, which evaluated the impact of remibrutinib (Rhapsido, Novartis) on symptom relief and control of chronic spontaneous urticaria (CSU).
Title
Program Chapters
Segment Chapters
Playlist:
advertisement
Recommended
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?